Mersana Therapeutics, Inc.

Mersana, a privately-held, venture-backed company, is focused on developing novel oncology agents based on the breakthrough discovery of Dr. Mikhail Papisov of Massachusetts General Hospital, who devised a biodegradable, bio-inert material called Fleximer that enhances the pharmacokinetics and safety of drugs. Mersana synthesizes and develops safer, more efficacious analogs of compounds with proven clinical efficacy using our Fleximer platform. Mersana solves the problems that limit or prevent clinical use and creates a novel pipeline with a significantly lower development risk profile. Mersana, formerly Nanopharma Corp., was co-founded by Dr. Papisov and PureTech Ventures, a life science venture creation fund. The Fleximer patents and six related patent families are licensed from the Massachusetts General Hospital.

Website

840 Memorial Drive
Cambridge, MA 02139 USA
617.498.0020